Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00339989 · ClinicalTrials.gov registry record
Cervical Cancer Early Endpoints and Determinants
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 3,013
- Enrollment target
NCT00339989: Completed study, sponsored by National Cancer Institute (NCI).
NCT00339989 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 3,013 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00339989 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 3,013 participants
- Enrollment target
Study Summary
This study, conducted by the National Cancer Institute and the University of Oklahoma, will look for changes in cervix cells and other samples that may be signs of cervical disease. Human papilloma virus, or HPV, is a common infection of the genitalia in women that usually goes away by itself. If HPV infection does not go away, it might turn into cancer of the cervix, although this is rare. This study will examine why many HPV infections go away and why a few persist and lead to cervical cancer. Women 18 years of age and older who are referred for colposcopy (examination of the vagina and cervix using an instrument with a magnifying lens) at the University of Oklahoma following Pap smear diagnosis may be eligible for this study. Women will be in one of the following diagnostic categories: * Cancer: Stage 1-2 only. * Precancer: Cervical intraepithelial neoplasia (CIN3). * HPV-infected: Positive for any of the 13 known cancer-causing HPV types, but not diagnosed with cancer or CIN3. * Normal: Negative for cancer-causing HPV and normal tissue laboratory results. Participants will undergo the following procedures: * Questionnaire: Covers demographic information (such as age, race, ethnicity, marital status, etc.), pregnancy history, menstrual and sexual history, contraceptive history, hormone medication history, medical history, smoking history, physical development, family history, and health care access. * Blood test: 2 tablespoons of blood drawn. * Colposcopy. * Procedure to collect a sample of cervical cells and fluids for HPV testing and research.
Primary Outcome
Cervical precancer and cancer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,013 participants |
| Start Date | 2003-09-12 |
| Est. Completion | 2020-03-11 |
What the finished NCT00339989 record still lists
NCT00339989 is an observational study that tracks outcomes without assigning an intervention. Its 3,013 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT00339989 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00339989 about?
NCT00339989 is a clinical study titled "Cervical Cancer Early Endpoints and Determinants". This study, conducted by the National Cancer Institute and the University of Oklahoma, will look for changes in cervix cells and other samples that may be signs of cervical disease. Human papilloma virus, or HPV, is a common infection of the genitalia in women that usually goes away by itself. If HP...
What is the current status of trial NCT00339989?
This trial is currently completed. The enrollment target is 3,013 participants. The study started on 2003-09-12. Estimated completion is 2020-03-11.
Who is sponsoring clinical trial NCT00339989?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI